Multi-Center Study Protocol: Impact of Sarcopenia in Early-Onset Colorectal Cancer.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-01-01

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sarcopenia's role in early-onset colorectal cancer (EOCRC), a subtype increasingly diagnosed in individuals under 50 years, has not yet been investigated according to recent literature.

Understanding the prevalence and prognostic impact of sarcopenia in EOCRC could inform tailored therapeutic approaches and improve patient outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Resistance Exercise and Creatine in Colorectal Cancer

NCT06420726

Colorectal Cancer

RECRUITING NA

Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.

NCT03843905

Colorectal Neoplasms Microbiota Prognosis +2 more

UNKNOWN

EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery

NCT06690606

Colorectal Cancer

NOT_YET_RECRUITING

A Comparative Study Between Early Onset Colorectal Cancer and Late Onset Colorectal Cancer Patients

NCT06326879

Colorectal Cancer

RECRUITING

Earlier Detection and Optimization of Treatment and Prognosis for Patients With Early-onset Colorectal Cancer

NCT06568679

Early-onset Colorectal Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As reported by the GLOBOCAN study, EOCRC occurs in individuals younger than 50 years old. According to the GLOBOCAN estimates, there were 188,069 new cases of EOCRC, with an Age Standardized Incidence Rate (ASRs) of 2.9 per 100,000 person-years worldwide. Recent evidence suggested an increasing incidence rate for EOCRC in different populations, with greater changes in both developed and developing countries. Despite the declining trend in the incidence of CRC in the total population of the developed countries, the incidence rates for EOCRC were increasing both in the developed and developing world. Sarcopenia's role in early-onset colorectal cancer (EOCRC), a subtype increasingly diagnosed in individuals under 50 years, remains underexplored.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Early Onset Colorectal Cancer Sarcopenia Prognostic Factors Overall Survival Disease-free Survival

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case group

Patients \< 50 years with diagnosis of colorectal cancer and with diagnosis of sarcopenia and CT-based assessment of skeletal muscle mass

Surgical resection

Intervention Type OTHER

Histologically confirmed EOCRC

Control group

patients \<50 years who had a CT- scan for suspected appendicitis or any other abdominal surgical urgency

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Surgical resection

Histologically confirmed EOCRC

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed EOCRC
* Emergency room access for suspected surgical pathology
* Age: 18-49 years at diagnosis.
* Available baseline CT or MRI scans for sarcopenia assessment

Exclusion Criteria

* Presence of comorbidity conditions severely affecting muscle mass unrelated to cancer (e.g., neuromuscular disorders).
* Inadequate follow-up data or loss to follow-up
* No past oncological history

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No